BMC Psychiatry
June 4, 2025
Yuekun Wu, Yue Ban, Guoliang Pan et al.
6 citations
Psychiatric healthcare workers experience prolonged exposure to psychological trauma and negative emotions, which ultimately predisposes them to mental health issues. The effectiveness of online mindfulness-based stress reduction training on depression and anxiety symptoms among psychiatric healthcare workers (HCWs) and the possible mechanisms that benefit these outcomes remain unclear. This...
Med
June 4, 2025
Felix Müller, Hannes Zaczek, Anna M Becker et al.
21 citations
This trial aimed to assess the efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with moderate-to-severe major depressive disorder. This was a randomized, parallel, double-blind, low-dose controlled trial (Clinicaltrials.gov: NCT03866252). Patients were randomly assigned in a 1:1 ratio to receive supportive psychotherapy and either 100 μg + 200 μg LSD or 25 μg + 25 μg...
Cells
June 3, 2025
Marta Jóźwiak-Bębenista, Anna Wiktorowska-Owczarek, Małgorzata Siatkowska et al.
4 citations
Despite affecting millions worldwide, major depressive disorder (MDD) remains a therapeutic challenge, with approximately one-third of patients failing to respond to standard treatments. The need for innovative, molecularly driven therapies has turned attention to ketamine and its enantiomers. While S-ketamine is clinically approved for treatment-resistant depression (TRD), it has various...
Pharmacopsychiatry
June 2, 2025
Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert et al.
1 citation
Ketamine and esketamine (ESK) offer new treatment options for resistant depression. Unlike traditional antidepressants, they can be used in combination with non-selective monoamine oxidase inhibitors (NS-MAOI) without the risk of serotonergic syndrome. However, potential sympathomimetic synergy may lead to elevated blood pressure (BP). This series investigates whether cardiovascular parameters...
Current Medicinal Chemistry
June 2, 2025
Jinlong Zhang, Xingxing Dang, Jiang Lin et al.
The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4- methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a...
Journal of Loss and Trauma
June 1, 2025
Lindsey M. Knowles, Deanna M Kaplan, Melissa Flores et al.
Abstract Grief is a profound life stressor that impacts multiple psychological outcomes. Mind-body interventions like Mindfulness Training (MT) and Progressive Muscle Relaxation (PMR) show promise for addressing negative psychological sequelae of grief. The present study investigated the effects of MT and PMR on secondary outcomes of grief including depressive symptoms, negative and positive...
The Brown University Psychopharmacology Update
June 1, 2025
Results of a systematic review and meta‐analysis suggest that esketamine has only modest efficacy in the treatment of adults with treatment‐resistant depression, with initial improvement diminishing after the first few days. The results also suggest no effect of esketamine on suicidality.
BJPsych Open
June 1, 2025
Ranjini Rao
Aims: 1. Examine efficacy and durability of antidepressant effects. 2. Identify specific symptoms of improvement. 3. Compare response rates and duration of antidepressant effects in failed to respond to previous treatments. Methods: Prospective review study of patients who received off-label rapid dissolve wafer for SL delivery in hospital setting 2–3 times a week for 4 weeks. The study...
BJPsych Open
June 1, 2025
Minna Chang, Allan H. Young, Mario F Juruena
Aims: Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although ketamine-induced cystitis...
Biuletyn Głównej Biblioteki Lekarskiej
June 1, 2025
Christian S. Skowron, Urszula Miłkowska, Gabriela Maria Piech et al.
Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conventional therapies often yielding suboptimal outcomes. This narrative review examines the therapeutic potential of psilocybin and ketamine, two novel agents offering distinct mechanisms of action compared to traditional monoamine-based or monoamine...